Science ❯ Neuroscience

Psychedelic Research

Psilocybin Studies Clinical Trials Drug Development Brain Function

AbbVie Agrees to Buy Gilgamesh’s Bretisilocin for Up to $1.2 Billion

The move positions the company to advance a shorter-acting psychedelic for major depression into late-stage testing.

Psilocybin Sessions Enhance Clergy Spirituality and Leadership Effectiveness